Aclaris Therapeutics, Inc. (ACRS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ACRS Revenue Growth
Revenue Breakdown (FY 2025)
ACRS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ACRS Revenue Analysis (2014–2025)
As of May 8, 2026, Aclaris Therapeutics, Inc. (ACRS) generated trailing twelve-month (TTM) revenue of $7.8 million, reflecting significant decline in growth of -85.9% year-over-year. The most recent quarter (Q4 2025) recorded $1.3 million in revenue, down 60.7% sequentially.
Looking at the longer-term picture, ACRS's 5-year compound annual growth rate (CAGR) stands at +3.8%, indicating moderate growth over time. The company achieved its highest annual revenue of $31.2 million in 2023.
Revenue diversification analysis shows ACRS's business is primarily driven by License and Service (76%), and Contract research (24%). With over half of revenue concentrated in License and Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NKTR (-43.9% YoY), PTGX (-91.5% YoY), and DAWN (+20.6% YoY), ACRS has underperformed the peer group in terms of revenue growth. Compare ACRS vs NKTR →
ACRS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ACRSCurrent | $8M | -85.9% | +3.8% | -975.9% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% | |
 DAWN | $158M | +20.6% | - | -80.8% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 DERM | $56M | -27.4% | +10.0% | -24.4% |
ACRS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.8M | -58.2% | $5.7M | 73.3% | $-76,375,000 | -975.9% |
| 2024 | $18.7M | -40.1% | $15.9M | 85.1% | $-141,932,000 | -758.2% |
| 2023 | $31.2M | +5.0% | $13.2M | 42.1% | $-97,357,000 | -311.6% |
| 2022 | $29.8M | +340.1% | $17.8M | 59.8% | $-89,854,000 | -302.0% |
| 2021 | $6.8M | +4.3% | $2.0M | 30.3% | $-89,723,000 | -1327.1% |
| 2020 | $6.5M | +53.3% | $1.3M | 20.8% | $-50,912,000 | -785.4% |
| 2019 | $4.2M | -58.1% | $172K | 4.1% | $-111,058,000 | -2627.3% |
| 2018 | $10.1M | +499.6% | $3.2M | 32.1% | $-135,414,000 | -1341.9% |
| 2017 | $1.7M | - | $476K | 28.3% | $-72,423,000 | -4303.2% |
| 2016 | $0 | - | $-120,000 | - | $-48,567,000 | - |
See ACRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACRS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACRS — Frequently Asked Questions
Quick answers to the most common questions about buying ACRS stock.
Is ACRS's revenue growth accelerating or slowing?
ACRS revenue declined -85.9% year-over-year, contrasting with the 5-year CAGR of +3.8%. TTM revenue fell to $8M. This reverses the prior growth trend.
What is ACRS's long-term revenue growth rate?
Aclaris Therapeutics, Inc.'s 5-year revenue CAGR of +3.8% reflects the variable expansion pattern. Current YoY growth of -85.9% is below this long-term average.
How is ACRS's revenue distributed by segment?
ACRS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.